Literature DB >> 2928805

Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.

M C Petti1, F Mandelli.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2928805

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  4 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 2.  Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1993-10       Impact factor: 4.981

3.  Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.

Authors:  P J Lobo; R L Powles; A Hanrahan; D K Reynold
Journal:  BMJ       Date:  1991-02-09

4.  Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.

Authors:  Juan Eduardo Megías-Vericat; David Martínez-Cuadrón; Joaquín Martínez López; Juan Miguel Bergua; Mar Tormo; Josefina Serrano; Ataulfo González; Jaime Pérez de Oteyza; Susana Vives; Belén Vidriales; Pilar Herrera; Juan Antonio Vera; Aurelio López Martínez; Adolfo de la Fuente; Ma Lourdes Amador; José-Ángel Hernández-Rivas; Ma Ángeles Fernández; Carlos Javier Cerveró; Daniel Morillo; Pilar Hernández Campo; Julián Gorrochategui; Daniel Primo; José Luis Rojas; Margarita Guenova; Joan Ballesteros; Miguel Sanz; Pau Montesinos
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-03-01       Impact factor: 2.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.